Macitentan

Routes
Oral (PO)
Half-Life (t½)
PO: 16h
Formula
C19H20Br2N6O4S
Molecular Weight
588.27 g/mol
PubChem CID
16004692
Aliases
Opsumit

Pharmacological Mechanism

Dual endothelin receptor antagonist — successor to bosentan with sustained tissue binding and once-daily dosing. PAH; hepatotoxicity is less than bosentan. Anemia + nasopharyngitis are the more common adverse effects.

Half-Life & Elimination Curve (PO: 16h)

100%50%25%12.5%0%0h0×t½16h1×t½32h2×t½48h3×t½64h4×t½3.3d5×t½0×t½ (0h): 100% remaining (~78.1 µg/L)1×t½ (16h): 50% remaining (~39 µg/L)2×t½ (32h): 25% remaining (~19.5 µg/L)3×t½ (48h): 12.5% remaining (~9.76 µg/L)4×t½ (64h): 6.3% remaining (~4.88 µg/L)5×t½ (3.3d): 3.1% remaining (~2.44 µg/L)
Plasma (PO)t½ Decay (16h)
  • 0×t½0h100% (78.1 µg/L)
  • 1×t½16h50% (39 µg/L)
  • 2×t½32h25% (19.5 µg/L)
  • 3×t½48h12.5% (9.76 µg/L)
  • 4×t½64h6.3% (4.88 µg/L)
  • 5×t½3.3d3.1% (2.44 µg/L)
Elimination t½16h (PO)
Rate Constant (ke)0.0433 h⁻¹
Time to Peak (Tmax)14.8h
Est. Peak (Cmax)78.1 µg/L
Clearance (CL)2.17 L/h
97% Washout (5×t½)3.3d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References